# Vitamine D en mortaliteit bij hartfalen: de EVITA 3-jaars gerandomiseerde trial

*geplaatst 2017-08-01 · Hartfalen · European heart journal · doi 10.1093/eurheartj/ehx235 · https://hartvaat.nl/2017/08/01/vitamine-d-en-mortaliteit-bij-hartfalen-de-evita-3-jaars-gerandomiseerde-trial/*

Gerandomiseerde 3-jaars trial die 4000 IU vitamine D per dag onderzocht bij hartfalen. Geen effect op totale mortaliteit — definitieve negatieve trial voor vitamine D bij HF.

## English: Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.

The EVITA trial showed that 4,000 IU daily vitamin D supplementation did not reduce all-cause mortality in heart failure patients despite correcting vitamin D deficiency. This definitive negative result argued against vitamin D as a heart failure therapy.

## Abstract (original, from the publication)

AIMS: Circulating 25-hydroxyvitamin D (25OHD) levels <75 nmol/L are associated with a nonlinear increase in mortality risk. Such 25OHD levels are common in heart failure (HF). We therefore examined whether oral vitamin D supplementation reduces mortality in patients with advanced HF. METHODS AND RESULTS: Four hundred HF patients with 25OHD levels <75 nmol/L were randomized to receive 4000 IU vitamin D daily or matching placebo for 3 years. Primary endpoint was all-cause mortality. Key secondary outcome measures included hospitalization, resuscitation, mechanical circulatory support (MCS) implant, high urgent listing for heart transplantation, heart transplantation, and hypercalcaemia. Initial 25OHD levels were on average <40 nmol/L, remained around 40 nmol/L in patients assigned to placebo and plateaued around 100 nmol/L in patients assigned to vitamin D. Mortality was not different in patients receiving vitamin D (19.6%; n = 39) or placebo (17.9%; n = 36) with a hazard ratio (HR) of 1.09 [95% confidence interval (CI): 0.69-1.71; P = 0.726]. The need for MCS implant was however greater in patients assigned to vitamin D (15.4%, n = 28) vs. placebo [9.0%, n = 15; HR: 1.96 (95% CI: 1.04-3.66); P = 0.031]. Other secondary clinical endpoints were similar between groups. The incidence of hypercalcaemia was 6.2% (n = 10) and 3.1% (n = 5) in patients receiving vitamin D or placebo (P = 0.192). CONCLUSION: A daily vitamin D dose of 4000 IU did not reduce mortality in patients with advanced HF but was associated with a greater need for MCS implants. Data indicate caution regarding long-term supplementation with moderately high vitamin D doses. TRIAL REGISTRATION INFORMATION: clinicaltrials.gov Idenitfier: NCT01326650.

Auteurs: Armin Zittermann, Jana B Ernst, Sylvana Prokop, Uwe Fuchs, Jens Dreier, Joachim Kuhn, Cornelius Knabbe, Ingvild Birschmann, Uwe Schulz, Heiner K Berthold, Stefan Pilz, Ioanna Gouni-Berthold, Jan F Gummert, Marcus Dittrich, Jochen Börgermann

---
Bron: European heart journal, https://doi.org/10.1093/eurheartj/ehx235. Bijgewerkt 2026-07-03T13:26:07Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.